Information  X 
Enter a valid email address

Realm Therapeutics PLC Ord 10P (RLM)

Date Time Source Announcement
14 Jun 2018 10:54 am
RNS
Result of AGM
31 May 2018 7:00 am
RNS
Realm to Present at June Investor Conferences
24 May 2018 7:00 am
RNS
Enrollment complete for Phase 2 study of PR022
23 May 2018 7:00 am
RNS
Filing with US SEC to Facilitate Nasdaq Listing
21 May 2018 7:00 am
RNS
Data Presentation at IID 2018
02 May 2018 12:39 pm
RNS
Annual Financial Report Available
  7:00 am
RNS
Final Results
  7:00 am
RNS
Realm Files Registration for Nasdaq Listing of ADS
26 Apr 2018 2:32 pm
RNS
Notice of Results
12 Mar 2018 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Clinical Update including PR013 Phase II results
08 Mar 2018 7:00 am
RNS
Presenting at Cowen Healthcare Conference
27 Feb 2018 7:00 am
RNS
Patent portfolio strengthened with USPTO allowance
20 Feb 2018 12:00 pm
RNS
Presentation at RBC Healthcare Conference
16 Feb 2018 7:00 am
RNS
Block listing Interim Review
15 Feb 2018 7:00 am
RNS
Clinical and Business Update
02 Jan 2018 7:00 am
RNS
Presents at 5th Annual Dermatology Summit
15 Dec 2017 7:00 am
RNS
Director/PDMR Shareholding
12 Dec 2017 7:00 am
RNS
First Patient Dosed in Phase 2 Study of PR013
05 Dec 2017 7:00 am
RNS
First Patient Dosed in Phase 2 Study of PR022
21 Nov 2017 7:00 am
RNS
Realm: Preclinical Data on PR022 Published
17 Nov 2017 7:00 am
RNS
Directorate Change
02 Nov 2017 7:00 am
RNS
Realm Therapeutics to Present at BIO-Europe? 2017
30 Oct 2017 7:00 am
RNS
Realm Presents Data at ACAAI Scientific Meeting
18 Oct 2017 7:00 am
RNS
Holding(s) in Company
  7:00 am
RNS
Block Listing Application
17 Oct 2017 6:28 pm
RNS
Holding(s) in Company
16 Oct 2017 3:39 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Realm Therapeutics to speak at BIO Investor Forum
13 Oct 2017 2:20 pm
RNS
Holding(s) in Company
  2:17 pm
RNS
Holding(s) in Company
12 Oct 2017 5:48 pm
RNS
Holding(s) in Company
  3:07 pm
RNS
Realm Therapeutics: Completion of �19.3m Placing
  11:04 am
RNS
Holding(s) in Company
  10:58 am
RNS
Holding(s) in Company
09 Oct 2017 11:35 am
RNS
Result of General Meeting
22 Sep 2017 7:00 am
RNS
Proposed Placing to raise �19.3 million
  7:00 am
RNS
Interim Results
21 Sep 2017 6:01 pm
RNS
Proposed Placing to raise �19.3 million
  6:00 pm
RNS
Interim Results
11 Sep 2017 7:00 am
RNS
FDA Permits PR013 to Proceed to Phase II Trial
07 Sep 2017 7:00 am
RNS
Conference Presentation
18 Aug 2017 7:00 am
RNS
Block listing Interim Review
02 Aug 2017 7:00 am
RNS
Submission of Investigational New Drug Application
06 Jul 2017 7:00 am
RNS
Presentation at World Congress on Inflammation
14 Jun 2017 7:09 am
RNS
Presentation at 2017 Marcum Microcap Conference
06 Jun 2017 11:05 am
RNS
Result of AGM
11 May 2017 12:21 pm
RNS
Notice of AGM
23 Mar 2017 2:57 pm
RNS
Annual Report and Accounts Available
  7:00 am
RNS
Final Results and Business Update
06 Mar 2017 7:00 am
RNS
Conference Presentation
28 Feb 2017 7:00 am
RNS
FDA permits PR022 to Proceed to Phase 2 Trial
20 Feb 2017 7:00 am
RNS
Block listing Interim Review
13 Feb 2017 7:00 am
RNS
Presentation at BIO CEO & Investor Conference
30 Jan 2017 7:00 am
RNS
Research Update - Submission of first IND
05 Jan 2017 7:00 am
RNS
Conference Presentations
04 Jan 2017 7:00 am
RNS
Grant of Options
21 Dec 2016 7:00 am
RNS
PDMR dealing
16 Dec 2016 7:00 am
RNS
Ivan Gergel appointed as Non-Executive Director
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t